Table 1.
Clinical outcomes of patients newly diagnosed with Ph+ ALL treated with TKI based therapies.
| Study (year) | N | Median age, [range] | Regimen | CR, % | CMR, % | AlloSCT in CR1, % | OS, % |
|---|---|---|---|---|---|---|---|
| Imatinib | |||||||
| Wassmann (2006) [8] | 45 | 41 [19–63] | GMALL | 96 | 52 (after induction) | 80 | 43 at 24 mo |
| Bassan (2010) [9] | 59 | 45 [20–66] | NILG 09/00 | 92 | 40 (3 mo) | 63 | 38 at 60 mo |
| Tanguy-Schmidt (2013) [10] | 45 | 45 [16–59] | GRAAPH 2003 | 96 | NA | 53 | 52 at 48 mo |
| Fielding (2014) [11] | 175 | 42 [16–64] | UKALLXII/ECOG2993 | 92 | NA | 46 | 38 at 48 mo |
| Chaladon (2015) [12] | 135 | 49 [18–59] | GRAAPH 2005 Vincristine and dexamethasone | 98 | 29 (2 cycles) | 60 | 48 at 60 mo |
| 133 | 45 [21–59] | GRAAPH 2005 hyperCVAD | 91 | 23 (2 cycles) | 60 | 43 at 60 mo | |
| Daver (2015) [13] | 54 | 51 [17–84] | hyperCVAD | 93 | 45 (3 mo) | 30 | 43 at 60 mo |
| Lim (2015) [14] | 87 | 41 [16–71] | Multiagent chemotherapy | 94 | 66 (at CR) | 64 | 33 at 60 mo |
| Hatta (2018) [15] | 99 | 45 [15–64] | JALSG ALL202 | 97 | 72 | 60 | 50 at 60 mo |
| Dasatinib | |||||||
| Foa (2011) [23] | 53 | 54 [24–76] | LAL1205 Corticosteroids | 93 | 15 (day 85) | 34 | 69 at 20 mo |
| Ravandi (2015) [21] | 72 | 55 [21–80] | hyperCVAD | 96 | 65 (3 mo) | 17 | 46 at 60 mo |
| Chiaretti (2015) [24] | 60 | 42 [19–59] | Corticosteroids ± chemotherapy | 97 | 19 (day 85) | NA | 58 at 36 mo |
| Ravandi (2016) [22] | 94 | 44 [20–60] | hyperCVAD | 88 | NA | 44 | 69 at 36 mo |
| Rousselot (2016) [25] | 71 | 69 [55–83] | EWALL Vincristine and dexamethasone | 96 | 24 | 10 | 36 at 60 mo |
| Nilotinib | |||||||
| Kim (2015) [27] | 90 | 47 [17–71] | Multiagent chemotherapy | 91 | 77 (3 mo) | 63 | 72 at 24 mo |
| Ponatinib | |||||||
| Jabbour (2015) [35] | 64 | 48 [21–80] | hyperCVAD | 100 | 77 (3 mo) | 16 | 76 at 36 mo |
Ph+ ALL, Philadelphia chromosome positive acute lymphoblastic leukemia; TKI, tyrosine kinase inhibitor; CR, complete remission; CMR, complete molecular remission; AlloHSCT in CR1, allogeneic hematopoietic stem cell transplantation in first remission; OS, overall survival; GMALL, German Multicentric Study Group for Adult ALL; NILG, Northern Italy Leukemia Group; GRAAPH, Group for Research on Adult Acute Lymphoblastic Leukemia; JALSG, Japan Adult Leukemia Study Group; hyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone; EWALL, European Working Group on adult ALL.